Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06690047 · ClinicalTrials.gov registry record · Phase 4
Treatment of Hereditary Angioedema Prodrome with Recombinant C1-esterase Inhibitor (Ruconest)
A Phase 4 study, sponsored by Bernstein Clinical Research Center.
- Completed
- Registry status
- Phase 4
- Development phase
- 5
- Enrollment target
NCT06690047 is a Phase 4 study that has completed, run by Bernstein Clinical Research Center. The registered enrollment target is 5 participants.
The verdict
NCT06690047, a Phase 4 study, has completed, sponsored by Bernstein Clinical Research Center.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 5 participants
- Enrollment target
Study Summary
To assess the efficacy of recombinant human C1-esterase inhibitor in the management of HAE prodrome for preventing the progression from prodrome to an acute angioedema attacks. Subjects will either receive Ruconest after the first 2 prodromes or during the last 2 prodromes. 5 clinic visits will occur within 24 hours of a prodrome. Subjects will complete prodrome severity and angioedema attack diaries
Interventions
- BIOLOGICAL Ruconest
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2018-08-14 |
| Est. Completion | 2022-04-28 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06690047
The ClinicalTrials.gov registry entry for NCT06690047 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 5 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bernstein Clinical Research Center, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Ruconest is the first listed.
NCT06690047 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06690047 about?
NCT06690047 is a clinical study titled "Treatment of Hereditary Angioedema Prodrome with Recombinant C1-esterase Inhibitor (Ruconest)". To assess the efficacy of recombinant human C1-esterase inhibitor in the management of HAE prodrome for preventing the progression from prodrome to an acute angioedema attacks. Subjects will either receive Ruconest after the first 2 prodromes or during the last 2 prodromes. 5 clinic visits will occu...
What is the current status of trial NCT06690047?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 5 participants. The study started on 2018-08-14. Estimated completion is 2022-04-28.
What interventions are being tested in trial NCT06690047?
The interventions under investigation include: Ruconest (BIOLOGICAL).
Who is sponsoring clinical trial NCT06690047?
This trial is sponsored by Bernstein Clinical Research Center, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.